Prof. Allan Klein (Cleveland Clinic, Cleveland, OH, USA) speaks to touchIMMUNOLOGY about recurrent pericarditis, the patient populations most frequently affected and current treatment options.
- What is the definition of recurrent pericarditis? (0:14)
- What are the causes of recurrent pericarditis and which patient populations are most frequently affected? (0:36)
- What are the limitations of current treatments for recurrent pericarditis? (1:21)
Disclosures: Prof. Allan Klein has acted as an advisor for Kiniska, Sobi and Pfizer, and received grant/ research support from Kiniksa.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Gina Furnival.
Filmed in coverage of virtual ACR Convergence 2021.
Share this Video
Related Videos In Rheumatic Diseases
Tonia Vincent, ACR 2021: Advances in Osteoarthritis Therapy
In this interview, we talk with Professor Tonia Vincent (Centre for Osteoarthritis Pathogenesis, University of Oxford, Oxford, UK) around how the therapeutic landscape in OA is changing. The presentation entitled ‘OA: New Horizons for Therapy.’ was given at the ACR Convergence, 3-9 November 2021. Questions How are new delivery systems for osteoarthritis drugs opening new […]
Tonia Vincent, ACR 2021: Updates in Therapeutics for Osteoarthritis
TouchIMMUNOLOGY were delighted to talk with Professor Tonia Vincent (Centre for Osteoarthritis Pathogenesis, University of Oxford, Oxford, UK) around her presentation titled ‘OA: New Horizons for Therapy‘, which was presented at the ACR Convergence, 3-9 November 2021. Questions Could you tell us a little about canakinumab and its promise in the treatment of osteoarthritis (OA)? […]
Allan Klein, ACR 2021: Rilonacept RHAPSODY Trial in Recurrent Pericarditis
It was a pleasure to discuss with Prof. Allan Klein (Cleveland Clinic, Cleveland, OH, USA) the results from the phase 3, RHAPSODY trial (NCT03737110) investigating the once-weekly IL-1α/IL-1β trap, rilonacept, in patients with recurrent pericarditis. The abstract entitled ‘RHAPSODY: Rilonacept, an IL-1α and IL-1β Trap, Resolves Pericarditis Episodes and Reduces Risk of Recurrence in a […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!